ONCOCOLLAPSE
Live / Registered — Registered (as of 11 May 2021)
What this means for you
Registered since 11 May 2021. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79292101
- Registration number
- 6344206
- Mark type
- Stylized text
- Filed
- 29 Jun 2020
- Published for opposition
- 23 Feb 2021
- Registered
- 11 May 2021
- Attorney of record
- Clifford D. Hyra
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical drugs based on peptides for treating oncological diseases; peptides as drugs to induce protein aggregation for treating oncological diseases; peptides as drugs to induce protein aggregation resulting in proteostatic collapse for treating oncological diseases
- Class 042 — Scientific and technological services: Medical and pharmaceutical research services; pharmaceutical research and development of pharmaceutical products and drugs based on peptides; pharmaceutical research and development of pharmaceutical products and drugs based on protein aggregation stimulating peptides; pharmaceutical research and development of pharmaceutical products and drugs based on aggregation stimulating peptides leading to proteostatic collapse
Owner
- AELIN THERAPEUTICS, BE
- AELIN THERAPEUTICS, BE
- AELIN THERAPEUTICS, BE
Prosecution history
- 24 Sept 2021 — NEW REPRESENTATIVE AT IB RECEIVED
- 20 Sept 2021 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 26 Aug 2021 — FINAL DISPOSITION NOTICE SENT TO IB
- 26 Aug 2021 — FINAL DISPOSITION PROCESSED
- 11 Aug 2021 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 11 May 2021 — REGISTERED-PRINCIPAL REGISTER
- 02 Apr 2021 — NEW REPRESENTATIVE AT IB RECEIVED
- 23 Feb 2021 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 23 Feb 2021 — PUBLISHED FOR OPPOSITION
- 03 Feb 2021 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 18 Jan 2021 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 15 Jan 2021 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 15 Jan 2021 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 15 Jan 2021 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 14 Nov 2020 — REFUSAL PROCESSED BY IB